Ignite Creation Date:
2025-12-25 @ 4:06 AM
Ignite Modification Date:
2026-02-20 @ 3:33 PM
Study NCT ID:
NCT03700320
Status:
COMPLETED
Last Update Posted:
2021-06-15
First Post:
2018-09-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Sponsor:
Allergan
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-08
Start Date Type:
ACTUAL
Primary Completion Date:
2020-05-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-05-21
Completion Date Type:
ACTUAL
First Submit Date:
2018-09-25
First Submit QC Date:
None
Study First Post Date:
2018-10-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-05-20
Results First Submit QC Date:
None
Results First Post Date:
2021-06-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-20
Last Update Post Date:
2021-06-15
Last Update Post Date Type:
ACTUAL